AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 152 filers reported holding AIMMUNE THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 1.27 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $12,886,000 | -42.2% | 771,126 | -50.1% | 0.08% | -53.6% |
| Q1 2020 | $22,276,000 | +24.9% | 1,544,812 | +81.4% | 0.18% | +66.1% |
| Q3 2019 | $17,837,000 | +64.6% | 851,813 | +63.7% | 0.11% | +91.2% |
| Q2 2019 | $10,835,000 | -26.2% | 520,416 | -15.2% | 0.06% | -20.8% |
| Q4 2018 | $14,674,000 | +40.7% | 613,461 | +60.4% | 0.07% | +67.4% |
| Q3 2018 | $10,431,000 | -77.0% | 382,380 | -77.4% | 0.04% | -76.2% |
| Q2 2018 | $45,411,000 | +32.1% | 1,688,783 | +56.4% | 0.18% | +25.7% |
| Q1 2018 | $34,373,000 | -26.7% | 1,079,900 | -12.9% | 0.14% | -28.7% |
| Q4 2017 | $46,868,000 | +72.2% | 1,239,246 | +12.9% | 0.20% | +66.9% |
| Q3 2017 | $27,222,000 | +32.9% | 1,098,087 | +10.2% | 0.12% | +5.2% |
| Q2 2017 | $20,483,000 | +38.2% | 996,232 | +46.1% | 0.12% | +38.6% |
| Q1 2017 | $14,819,000 | +77.7% | 681,973 | +67.3% | 0.08% | +43.1% |
| Q4 2016 | $8,337,000 | – | 407,700 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 3,967,900 | $42,933,000 | 29.35% |
| TLP GROUP LLC | 2,833,285 | $30,656,000 | 20.86% |
| Aisling Capital LLC | 2,990,000 | $32,352,000 | 7.64% |
| Vivo Capital, LLC | 763,009 | $8,256,000 | 2.26% |
| RA Capital Management | 1,292,940 | $13,990,000 | 1.94% |
| Foresite Capital Management III, LLC | 235,020 | $2,543,000 | 1.74% |
| Palo Alto Investors LP | 325,599 | $3,523,000 | 0.27% |
| Rock Springs Capital Management LP | 293,000 | $3,170,000 | 0.24% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 332,625 | $3,599,000 | 0.20% |
| Virtus ETF Advisers LLC | 19,501 | $211,000 | 0.16% |